decitabine mechanism of action
Published 2 years ago • 961 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
3:21
mode of action of hypomethylating agents for mds
-
1:37
dr. saunthararajah on mechanisms of resistance to 5-azacytidine/decitabine in mds-aml
-
6:21
decitabine and venetoclax for aml
-
2:33
decitabine dosing regimens in older aml patients: 5-day vs. 10-day, is there a difference?
-
1:03
10-day astx727 (decitabine/cedazuridine) with venetoclax in the treatment of r/r aml
-
7:49
mechanisms of resistance to 5-azacytidine/decitabine in mds-aml
-
2:34
decitabine plus venetoclax is comparable to intensive chemotherapy in r/r aml
-
8:35
effect of bmt status on decitabine plus ipilimumab in r/r mds/aml
-
2:02
what are hypomethylating agents and when are they used for mds?
-
1:37
phase i trial of decitabine plus ipilimumab in r/r mds & aml
-
0:30
decitabine - dacogen use in a nutshell.
-
5:45
azacitidine and decitabine in treatment naive aml patients
-
2:05
venetoclax with decitabine for high-risk aml and mds
-
4:15
phase ib/ii trial of quizartinib, decitabine and venetoclax in flt3-itd-mutated aml
-
2:23
oral combination of astx727 (decitabine/cedazuridine) plus ven for older/unfit patients with aml
-
2:06
onvansertib with cytarabine or decitabine for r/r aml
-
2:36
outcomes of tp53-mutant aml with venetoclax and decitabine
-
0:45
oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with aml
-
3:55
decitabine vs hydroxyurea for advanced proliferative cmml